Market Access Impact (US) [Asthma/COPD]
Two brands enjoy big market share boosts as market barriers hinder competitors
Market barriers affect more than a third of asthma/COPD prescriptions in the US. According to our survey, roughly 55% of doctors can’t prescribe certain brands because they’re either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of almost 5% because doctors can’t prescribe competitors.
Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 100 US-based pulmonologists and primary care physicians, the report covers 12 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, and Roche.
Top Takeaways
Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access
We surveyed 100 US-based pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.
All respondents have
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Market barriers affect more than a third of asthma/COPD prescriptions in the US. According to our survey, roughly 55% of doctors can’t prescribe certain brands because they’re either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of almost 5% because doctors can’t prescribe competitors.
Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 100 US-based pulmonologists and primary care physicians, the report covers 12 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, and Roche.
Top Takeaways
- Barriers affect more than a third of prescriptions: The two biggest barriers have a bigger impact than all other barriers combined.
- Two brands see impressive market share gains: Each sees a net increase of nearly 5% because barriers prevent doctors from prescribing competing treatments.
- Most brands lose: 8 of the 12 surveyed brands see a net market share loss, although many of those losses are modest.
- Few brands are widely prescribed: Only 4 brands are prescribed by more than about 65% of doctors. However, many doctors are willing to consider brands they don’t prescribe.
- More doctors experience cost and formulary availability barriers: Roughly 20-40% of doctors can’t prescribe most brands because they’re too expensive or not available on formularies.
- Low awareness is a problem for some brands: 20-30% of doctors simply haven’t heard of 4 of the surveyed brands.
- Symbicort (budesonide/formoterol; AstraZeneca)
- Advair (fluticasone/salmetrol; GSK)
- Spiriva (tiotropium; Boehringer Ingelheim)
- Tudorza (aclidinium; AstraZeneca)
- Anoro (umeclidinium/vilanterol; GSK)
- Arcapta (indacaterol; Novartis)
- Utibron (indacaterol/glycopyrronium; Novartis)
- Seebri (glycopyrronium; Novartis)
- Daliresp (roflumilast; AstraZeneca)
- Nucala (mepolizumab; GSK)
- Xolair (omalizumab; Novartis/Roche)
- Breo Ellipta (vilanterol/fluticasone furoate; GSK)
Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 100 US-based pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.
All respondents have
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with asthma and/or COPD in total in the last month
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1.WHAT ARE MARKET BARRIERS?
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
2.ABOUT THIS REPORT
3.ABOUT THE SURVEY
4.BRANDS INCLUDED IN THE SURVEY
5.EXECUTIVE SUMMARY
